Quantcast
Last updated on April 24, 2014 at 17:35 EDT

Latest Autoimmunity Stories

2013-07-18 23:26:34

Without a doubt, “X” does make a difference. The Society for Women’s Health Research (SWHR) held its 4th annual "What a Difference an X Makes: The State of Women’s Health Research" scientific conference at the Pew Charitable Trust Conference Center, Washington DC, July 18th -19th; to increase awareness and urgency about the importance of sex differences in chronic disease prevention, diagnosis, and treatment, and to ultimately transform disease research to accelerate...

2013-07-17 16:27:42

AbGenomics raised new fund for advancing its clinical trials and new linker-payload technology LOS ALTOS, Calif., July 17, 2013 /PRNewswire-iReach/ -- AbGenomics International announced today that it has raised $9.6 million in current financing round. (Photo: http://photos.prnewswire.com/prnh/20130717/MN49038) AbGenomics will use the proceeds to continue advancing its therapeutic antibodies for autoimmune diseases and cancers. AbGenomics' lead drug candidate AbGn-168H, a...

2013-07-10 12:28:27

Nature Paper by Team at RIKEN and Vedanta Shows Efficacy of Candidate in Autoimmune Diseases BOSTON, July 10, 2013 /PRNewswire/ -- Scientists have described one of the first instances of a rationally designed drug candidate derived from the human microbiota. The work was led by Dr. Kenya Honda, Team Leader of the Laboratory for Intestinal Homeostasis at the RIKEN Center for Integrative Medical Sciences (IMS) and scientific co-founder of Vedanta Biosciences. The paper describing the...

2013-07-10 12:27:43

VANCOUVER, July 10, 2013 /PRNewswire/ - viDA Therapeutics Inc. (viDA), a private biotechnology company, is pleased to announce the closing of a $1.8 million equity financing round. viDA is pursuing the discovery and development of novel, first-in-class drugs that inhibit the granzyme family of serine proteases for the treatment of several chronic inflammatory and age-related diseases.  The financing was led by BDC Venture Capital and included support from a number of angel...

2013-07-03 16:22:24

St. Jude Children's Research Hospital study challenges prior understanding of the process regulating specialized T cells that are essential for a balanced immune system MEMPHIS, Tenn., July 3, 2013 /PRNewswire-USNewswire/ -- New findings from St. Jude Children's Research Hospital reveal an unconventional control mechanism involved in the production of specialized T cells that play a critical role in maintaining immune system balance. The research appears in the current online...

2013-07-01 15:04:38

A team led by scientists at The Scripps Research Institute (TSRI) has identified a family of tiny RNA molecules that work as powerful regulators of the immune response in mammals. Mice who lack these RNA molecules lose their normal infection-fighting ability, whereas mice that overproduce them develop a fatal autoimmune syndrome. "This finding gives us insights into immune regulation that could be very helpful in a range of medical applications, from viral vaccines to treatments for...

2013-06-27 12:28:35

WASHINGTON, June 27, 2013 /PRNewswire-USNewswire/ -- Mark J. Shlomchik, M.D., Ph.D., the incoming Chair of Immunology at the University of Pittsburgh, was honored Thursday as the first recipient of the Lupus Insight Prize, the first-of-a-kind award for use in innovative research on lupus, an unpredictable and sometimes fatal autoimmune disease that affects an estimated 1.5 million Americans. Dr. Shlomchik received the Prize during a formal ceremony at FOCIS 2013, the 13th Annual...

2013-06-27 12:27:52

SEATTLE, June 27, 2013 /PRNewswire/ -- Adaptive Biotechnologies announced today that it has signed an agreement with Biogen Idec for the study of the immune repertoire and the search for immunological biomarkers in difficult to treat autoimmune diseases. (Logo: http://photos.prnewswire.com/prnh/20120103/SF28632LOGO) Under the collaboration, Adaptive's proprietary immune profiling assay, immunoSEQ, will be used to characterize the immune repertoire of patient samples with...

2013-06-26 16:24:26

--Novel Approach May Have Potential to Revolutionize Treatment of Certain Autoimmune Diseases By Selectively Neutralizing Destructive Self-Antigens While Leaving Rest of Immune System Unaffected-- PORTOLA VALLEY, Calif., June 26, 2013 /PRNewswire/ -- Tolerion Inc., today announced the publication of results from a Phase 2 trial demonstrating that lead product TOL-3021 may have the potential to alleviate or even shut down the destructive disease process in type 1...

2013-06-24 19:38:34

Nature-published study reveals previously unknown role of septin proteins A major study from researchers at the La Jolla Institute for Allergy and Immunology provides new revelations about the intricate pathways involved in turning on T cells, the body's most important disease-fighting cells, and was published today in the prestigious scientific journal Nature. The La Jolla Institute team is the first to prove that a certain type of protein, called septins, play a critical role in...